Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Opuntia ficus-indica is a species of cactus, commonly known as prickly pear or nopal, traditionally used as a food and folk medicine ingredient. It contains polyphenols, vitamins, betalains, flavonoids, and polysaccharides. Its components have demonstrated antioxidant, anti-inflammatory, hypoglycemic, hypolipidemic, antimicrobial, neuroprotective, wound-healing, hepatoprotective, anti-obesity, and gastroprotective effects in preclinical and limited clinical studies. Its mechanisms are primarily attributed to antioxidant and anti-inflammatory pathways, and it is being evaluated for potential supportive roles in diabetes, metabolic syndrome, benign prostatic hyperplasia, alcohol-induced hangover, hyperlipidemia, and wound healing. It is available as food, dietary supplement, and topical preparations, but not as a conventional pharmaceutical drug[1][2][3][4][5][7][8][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on opuntia ficus-indica.